SPEAKERS
Gabriel Festoc
Dr. Gabriel Festoc was in 2000 the founder Chairman & CEO of GeneSystems (now part of the Pall Corporation). In 2009, he joined Polyplus-transfection® as Chairman. In addition, Gabriel has worked as a senior consultant for a number of biotechnology companies and financial investors and he is the Co-Founder of BAOLABS.
Fabien Moncaubeig
Fabien has led several collaborative projects of evaluation (GSK Biologicals), characterization (Artelis) and then development (Artelis/ATMI) of bioreactors. As a Sr Application Specialist he is now advising, designing and managing the transfer, development and scale up of customer processes (from antibody production and cellular therapy to vaccine manufacturing) into ATMI cell culture platforms.
Matthias Hebben
After obtaining his diploma of Engineer in Biotechnologies in 1998 and his PhD in molecular and cell biology in 2001, Matthias Hebben occupied several positions related to the Virology field in pharmaceutical industries and a biotech company: Scientist at VIRBAC, Preclinical Specialist at INTERVET-SCHERING PLOUGH and Head of Virology at VIVALIS.Since January 2013, Matthias leads the Bioprocess Development Department at Genethon, a French non-profit organization.
Bertrand Coissac
Bertrand Coissac (M.S., MBA) has served over 10 years in a variety of international sales and marketing leadership positions with Genzyme, GeneSystems and Pall Corporation. Bertrand has founded in 2011 Asia Bio Channel Ltd which supports Life Sciences companies develop and execute their market entry strategy in the highly competitive Asia-Pacific markets. Bertrand is also the Co-Founder and CEO of BAOLABS
Olivier Nègre
After a first experience in research at Cochin Hospital-Paris, Olivier got a PhD in Therapeutic biotechnologies (Gene and Cell Therapy) from Saint-Louis Hospital in 2006. He joined in 2005 BlueBird Bio France (formely Genetix Pharmaceuticals Inc.) as team leader.
Oliver has been involved in more than 15 publications and posters dealing with cell & gene therapy.
Zaki Sellam
Based in Basel, I am Managing Director of ESN Life Sciences. Having worked with Biotechnology companies from early stage through to commercialization, I have both technical and management experience to the strategic partnerships developed within my practice. I focuse primarily on supporting innovative start-up organizations in the Biotechnology.
François Busquet
After graduating in 2003 from ENSTBB, I pursued my studies with a PhD in life sciences. I have worked abroad for the last 10 years in the field of toxicology/safety testing for the private sector, governmental organisation as well as academia. My specialty areas cover 1) alternatives to animal testing or 3Rs 2) regulatory toxicology and 3) ecotoxicology.
Vincent Lombardi
Cellular immunologist specialized in allergic diseases with a strong background in biotechnology. After a Master degree in Biotechnology, a PhD and a post-doc in Immunology, I joined Stallergenes as the leader of the Immunomonitoring group. The goal of my team is to identify new biomarkers to predict / follow-up allergen immunotherapy efficacy.
Nicolas Fouque
Graduated as biotechnology engineer in 2006 at the ENSTBB, I joined Novimmune as cell culture assistant to establish technologies for generation of high yield CHO stable cell lines and fermentation processes to support multiple mAb projects. Since 2010, I am acting as manufacturing project manager and heading a group responsible for upstream/downstream process development, up to 200 litre scale production and process validation studies.
OTHER SPEAKERS
Véronique Blanc, Head of Biologic Discovery at SANOFI
Yvan Gouttebelle, Co-Founder at THE BIOTECH QUALITY GROUP S.A.
Cedric Geyer, MERCK MILLIPORE